Selective serotonin reuptake inhibitors use and the risk of hepatocellular carcinoma: a systematic review and dose-response analysis of cohort studies with one million participants
Language English Country Germany Media print-electronic
Document type Letter, Comment
PubMed
35274148
DOI
10.1007/s00228-022-03309-y
PII: 10.1007/s00228-022-03309-y
Knihovny.cz E-resources
- MeSH
- Carcinoma, Hepatocellular * epidemiology MeSH
- Serotonin and Noradrenaline Reuptake Inhibitors * MeSH
- Cohort Studies MeSH
- Humans MeSH
- Liver Neoplasms * chemically induced epidemiology MeSH
- Selective Serotonin Reuptake Inhibitors adverse effects MeSH
- Systematic Reviews as Topic MeSH
- Check Tag
- Humans MeSH
- Publication type
- Letter MeSH
- Comment MeSH
- Names of Substances
- Serotonin and Noradrenaline Reuptake Inhibitors * MeSH
- Serotonin Uptake Inhibitors MeSH
Department of Psychological Sciences University of Bristol Bristol BS8 1TH UK
Health Research Institute University of Canberra Canberra Australia
Sydney Pharmacy School The University of Sydney Camperdown Sydney NSW Australia
See more in PubMed
Chen VC, Lin CF, Hsieh YH, Liang HY, Huang KY, Chiu WC, Lee Y, McIntyre RS, Chan HL (2017) Hepatocellular carcinoma and antidepressants: a nationwide population-based study. Oncotarget 8(18):30464–30470. https://doi.org/10.18632/oncotarget.12826 PubMed DOI
Bhagavathula AS, Woolf B, Rahmani J, Vidyasagar K, Tesfaye W (2022) Selective serotonin reuptake inhibitor use and the risk of hepatocellular carcinoma: a systematic review and dose–response analysis of cohort studies with one million participants. Eur J Clin Pharmacol 1–9
Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR (2019) A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16(10):589–604. https://doi.org/10.1038/s41575-019-0186-y PubMed DOI PMC